anastrozole has been researched along with Pneumonia in 1 studies
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression." | 9.69 | Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. ( Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM, 2023) |
| "Patients with histologically confirmed, untreated ER+/HER2- breast cancer, primary tumour ≥2 cm, ECOG performance status ≤1, and eligible for post-treatment surgery received nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg or 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles, or until disease progression." | 5.69 | Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. ( Ades, F; Filian, J; Huang, N; Jerusalem, G; Mazzei-Abba, A; Nikolinakos, P; Prat, A; Reinisch, M; Ruiz-Borrego, M; Salgado, R; Saura, C; Tolaney, SM, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jerusalem, G | 1 |
| Prat, A | 1 |
| Salgado, R | 1 |
| Reinisch, M | 1 |
| Saura, C | 1 |
| Ruiz-Borrego, M | 1 |
| Nikolinakos, P | 1 |
| Ades, F | 1 |
| Filian, J | 1 |
| Huang, N | 1 |
| Mazzei-Abba, A | 1 |
| Tolaney, SM | 1 |
1 trial available for anastrozole and Pneumonia
| Article | Year |
|---|---|
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoad | 2023 |